RadNet Reports Record Q1 2026 Earnings Amid Weather Challenges
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 49 minutes ago
0mins
Should l Buy RDNT?
Source: seekingalpha
- Record Performance: RadNet achieved record revenue and adjusted EBITDA in Q1 2026, despite an estimated $13 million revenue and $9 million EBITDA loss due to severe weather, demonstrating the company's resilience and sustained market demand even in challenging conditions.
- Significant Procedure Growth: PET/CT procedures increased by 35.2% year-over-year, with same-center growth of 14.7%, and 29.3% of procedural volume coming from advanced imaging, indicating an expanding market share in high-end medical services and enhancing future revenue potential.
- Strong Cash Flow and Financial Health: By the end of Q1, RadNet reported $455.3 million in cash and reduced DSO to a record low of 29.5 days, showcasing exceptional performance in liquidity management and financial health, providing ample funding for future investments.
- Rapid Growth in Digital Health: The Digital Health segment achieved $97 million in annual recurring revenue (ARR), representing a 95% year-over-year growth, with expectations to exceed $140 million by year-end, indicating significant progress in the company's strategic positioning in digital healthcare.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy RDNT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on RDNT
Wall Street analysts forecast RDNT stock price to rise
6 Analyst Rating
6 Buy
0 Hold
0 Sell
Strong Buy
Current: 58.190
Low
86.00
Averages
90.17
High
95.00
Current: 58.190
Low
86.00
Averages
90.17
High
95.00
About RDNT
RadNet, Inc. is a national provider of fixed-site diagnostic imaging services in the United States. The Company has a network of 407 owned and/or operated outpatient imaging centers. Its Imaging Center segment provides physicians with imaging capabilities to facilitate the diagnosis and treatment of diseases and disorders. Its services include magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), nuclear medicine, mammography, ultrasound, diagnostic radiology (X-ray), fluoroscopy and other related procedures. Its Digital Health segment develops and deploys clinical applications to enhance interpretation of medical images and improve patient outcomes with an emphasis on brain, breast, prostate, and pulmonary diagnostics. It provides radiology information technology and artificial intelligence (AI) solutions marketed under the DeepHealth brand and teleradiology professional services. It is also a provider of AI-powered breast health solutions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
RadNet Reports Record Q1 2026 Earnings Amid Weather Challenges
- Record Performance: RadNet achieved record revenue and adjusted EBITDA in Q1 2026, despite an estimated $13 million revenue and $9 million EBITDA loss due to severe weather, demonstrating the company's resilience and sustained market demand even in challenging conditions.
- Significant Procedure Growth: PET/CT procedures increased by 35.2% year-over-year, with same-center growth of 14.7%, and 29.3% of procedural volume coming from advanced imaging, indicating an expanding market share in high-end medical services and enhancing future revenue potential.
- Strong Cash Flow and Financial Health: By the end of Q1, RadNet reported $455.3 million in cash and reduced DSO to a record low of 29.5 days, showcasing exceptional performance in liquidity management and financial health, providing ample funding for future investments.
- Rapid Growth in Digital Health: The Digital Health segment achieved $97 million in annual recurring revenue (ARR), representing a 95% year-over-year growth, with expectations to exceed $140 million by year-end, indicating significant progress in the company's strategic positioning in digital healthcare.
See More
RadNet (RDNT) Q1 2026 Earnings Transcript
See More
RadNet Reports Strong Q1 Results with Revised 2026 Outlook
- Significant Revenue Growth: RadNet reported net revenues of $576.63 million in Q1 2026, a substantial increase from $471.40 million in the same quarter last year, indicating strong demand and market expansion in the diagnostic imaging sector.
- Narrowing Losses: The company recorded a net loss of $24.73 million, or $0.43 per share, in Q1 2026, which is an improvement compared to a loss of $29.74 million, or $0.51 per share, in Q1 2025, suggesting progress in cost control and operational efficiency.
- Improved EBITDA: Adjusted EBITDA reached $63.26 million, up from $46.40 million a year earlier, reflecting ongoing enhancements in profitability and operational efficiency within the company.
- Optimistic 2026 Outlook: RadNet expects revenues to range between $2.355 billion and $2.405 billion for 2026, a significant increase from $2.040 billion in 2025, while adjusted EBITDA is projected to be between $340 million and $353 million, highlighting strong future growth potential.
See More
RadNet Reports Strong Q1 2026 Financial Results with 22.1% Revenue Growth
- Significant Revenue Growth: In Q1 2026, RadNet achieved total revenue of $575.6 million, reflecting a 22.1% year-over-year increase, primarily driven by a rebound in advanced imaging procedural volumes, showcasing the company's strong recovery capabilities in the market.
- Digital Health Segment Outperformance: The Digital Health segment reported a 51.5% increase in revenue to $29.1 million, although Adjusted EBITDA decreased to $1.3 million, indicating that ongoing investments in digital transformation are yielding positive results despite short-term challenges.
- Substantial EBITDA Improvement: The Adjusted EBITDA for Q1 2026 reached $63.3 million, a 36.3% increase compared to the same period last year, reflecting significant enhancements in operational efficiency and cost control, which bolster expectations for future profitability.
- Optimistic Future Outlook: RadNet revised its Imaging Center guidance for 2026, anticipating further growth in revenue and free cash flow, demonstrating confidence in future market demand, particularly through its partnership with Trinity Health, which will further drive the implementation of digital health solutions.
See More
RadNet Executive Sells 15,000 Shares Amid Market Fluctuations
- Executive Sell-Off: Chief Strategy Officer Gregory Sorensen sold 15,000 shares of RadNet on March 18 through multiple open-market transactions, totaling approximately $932,000, resulting in a 1.21% decrease in direct holdings to 1,223,923 shares, indicating a cautious outlook on the company's future.
- Transaction Context: This sale marks Sorensen's only open-market transaction in the past nine months, following a significant sale of 100,000 shares last May, suggesting that current market conditions may be influencing executive decisions, especially as RadNet's stock has declined about 12% in 2026.
- Company Financial Performance: RadNet reported over $2 billion in revenue for 2025, an 11.5% increase year-over-year, alongside adjusted EBITDA of $20.8 million, up 7.4%, highlighting strong growth potential in both its imaging center and digital health segments, with projected 18% revenue growth for the imaging center segment.
- Investor Takeaway: Despite Sorensen's share reduction, he retains over 1.2 million shares, indicating alignment with shareholder interests, and investors should focus on the company's performance in imaging volumes and software growth, as the recent stock decline may reflect market sentiment rather than fundamental changes.
See More
RadNet Insider Sells Shares Amid Market Skepticism
- Insider Trading: On March 18, 2026, RadNet's Chief Strategy Officer Gregory Sorensen sold 15,000 shares for approximately $932,000, indicating a cautious outlook on the company's future amidst market volatility.
- Ownership Adjustment: This sale reduced Sorensen's holdings by just over 1%, yet he retains over 1.2 million shares, suggesting he remains aligned with shareholder interests despite the recent stock decline.
- Company Performance Overview: RadNet reported full-year revenue exceeding $2 billion for 2025, an 11.5% increase year-over-year, alongside adjusted EBITDA of $20.8 million, up 7.4%, highlighting the company's growth potential in the medical imaging sector.
- Market Reaction Analysis: Despite solid fundamentals, RadNet's stock has fallen about 12% in 2026, reflecting investor skepticism, prompting a need for careful evaluation of both internal and external factors affecting stock performance.
See More
RadNet Reports Record Q1 2026 Earnings Amid Weather Challenges
- Record Performance: RadNet achieved record revenue and adjusted EBITDA in Q1 2026, despite an estimated $13 million revenue and $9 million EBITDA loss due to severe weather, demonstrating the company's resilience and sustained market demand even in challenging conditions.
- Significant Procedure Growth: PET/CT procedures increased by 35.2% year-over-year, with same-center growth of 14.7%, and 29.3% of procedural volume coming from advanced imaging, indicating an expanding market share in high-end medical services and enhancing future revenue potential.
- Strong Cash Flow and Financial Health: By the end of Q1, RadNet reported $455.3 million in cash and reduced DSO to a record low of 29.5 days, showcasing exceptional performance in liquidity management and financial health, providing ample funding for future investments.
- Rapid Growth in Digital Health: The Digital Health segment achieved $97 million in annual recurring revenue (ARR), representing a 95% year-over-year growth, with expectations to exceed $140 million by year-end, indicating significant progress in the company's strategic positioning in digital healthcare.
See More
RadNet (RDNT) Q1 2026 Earnings Transcript
See More
RadNet Reports Strong Q1 Results with Revised 2026 Outlook
- Significant Revenue Growth: RadNet reported net revenues of $576.63 million in Q1 2026, a substantial increase from $471.40 million in the same quarter last year, indicating strong demand and market expansion in the diagnostic imaging sector.
- Narrowing Losses: The company recorded a net loss of $24.73 million, or $0.43 per share, in Q1 2026, which is an improvement compared to a loss of $29.74 million, or $0.51 per share, in Q1 2025, suggesting progress in cost control and operational efficiency.
- Improved EBITDA: Adjusted EBITDA reached $63.26 million, up from $46.40 million a year earlier, reflecting ongoing enhancements in profitability and operational efficiency within the company.
- Optimistic 2026 Outlook: RadNet expects revenues to range between $2.355 billion and $2.405 billion for 2026, a significant increase from $2.040 billion in 2025, while adjusted EBITDA is projected to be between $340 million and $353 million, highlighting strong future growth potential.
See More
RadNet Reports Strong Q1 2026 Financial Results with 22.1% Revenue Growth
- Significant Revenue Growth: In Q1 2026, RadNet achieved total revenue of $575.6 million, reflecting a 22.1% year-over-year increase, primarily driven by a rebound in advanced imaging procedural volumes, showcasing the company's strong recovery capabilities in the market.
- Digital Health Segment Outperformance: The Digital Health segment reported a 51.5% increase in revenue to $29.1 million, although Adjusted EBITDA decreased to $1.3 million, indicating that ongoing investments in digital transformation are yielding positive results despite short-term challenges.
- Substantial EBITDA Improvement: The Adjusted EBITDA for Q1 2026 reached $63.3 million, a 36.3% increase compared to the same period last year, reflecting significant enhancements in operational efficiency and cost control, which bolster expectations for future profitability.
- Optimistic Future Outlook: RadNet revised its Imaging Center guidance for 2026, anticipating further growth in revenue and free cash flow, demonstrating confidence in future market demand, particularly through its partnership with Trinity Health, which will further drive the implementation of digital health solutions.
See More
RadNet Executive Sells 15,000 Shares Amid Market Fluctuations
- Executive Sell-Off: Chief Strategy Officer Gregory Sorensen sold 15,000 shares of RadNet on March 18 through multiple open-market transactions, totaling approximately $932,000, resulting in a 1.21% decrease in direct holdings to 1,223,923 shares, indicating a cautious outlook on the company's future.
- Transaction Context: This sale marks Sorensen's only open-market transaction in the past nine months, following a significant sale of 100,000 shares last May, suggesting that current market conditions may be influencing executive decisions, especially as RadNet's stock has declined about 12% in 2026.
- Company Financial Performance: RadNet reported over $2 billion in revenue for 2025, an 11.5% increase year-over-year, alongside adjusted EBITDA of $20.8 million, up 7.4%, highlighting strong growth potential in both its imaging center and digital health segments, with projected 18% revenue growth for the imaging center segment.
- Investor Takeaway: Despite Sorensen's share reduction, he retains over 1.2 million shares, indicating alignment with shareholder interests, and investors should focus on the company's performance in imaging volumes and software growth, as the recent stock decline may reflect market sentiment rather than fundamental changes.
See More
RadNet Insider Sells Shares Amid Market Skepticism
- Insider Trading: On March 18, 2026, RadNet's Chief Strategy Officer Gregory Sorensen sold 15,000 shares for approximately $932,000, indicating a cautious outlook on the company's future amidst market volatility.
- Ownership Adjustment: This sale reduced Sorensen's holdings by just over 1%, yet he retains over 1.2 million shares, suggesting he remains aligned with shareholder interests despite the recent stock decline.
- Company Performance Overview: RadNet reported full-year revenue exceeding $2 billion for 2025, an 11.5% increase year-over-year, alongside adjusted EBITDA of $20.8 million, up 7.4%, highlighting the company's growth potential in the medical imaging sector.
- Market Reaction Analysis: Despite solid fundamentals, RadNet's stock has fallen about 12% in 2026, reflecting investor skepticism, prompting a need for careful evaluation of both internal and external factors affecting stock performance.
See More
